Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Curr Psychiatry Rep ; 2024 Jun 06.
Article in English | MEDLINE | ID: mdl-38842654

ABSTRACT

PURPOSE OF REVIEW: This article will provide clinicians with guidance on helping older adult patients make lifestyle changes to enhance brain health and well-being. RECENT FINDINGS: Evidence suggests that physical activity might be helpful in improving cognitive functioning. The data on the benefits of cognitive activity is inconsistent and not as robust. The MediDiet, DASH, and MIND diets have been associated with better cognitive health. Sleep hygiene and cognitive behavioral therapies are considered first line evidence-based treatments for insomnia and the maintenance of healthy sleep patterns. Mindfulness based interventions have been shown to reduce anxiety, depression, and stress, and can help some older adults manage pain more constructively. Evidence-based information regarding the four topics of exercise, nutrition, sleep, and mindfulness is reviewed, so that clinicians may be better able to optimize care for their older adult patients.

2.
Am J Geriatr Psychiatry ; 27(9): 1031-1033, 2019 09.
Article in English | MEDLINE | ID: mdl-31262685

Subject(s)
Imagination
4.
J Am Geriatr Soc ; 62(3): 558-61, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24397784

ABSTRACT

Professional and advocacy organizations have long urged that dementia should be recognized and properly diagnosed. With the passage of the National Alzheimer's Project Act in 2011, an Advisory Council for Alzheimer's Research, Care, and Services was convened to advise the Department of Health and Human Services. In May 2012, the Council produced the first National Plan to address Alzheimer's disease, and prominent in its recommendations is a call for quality measures suitable for evaluating and tracking dementia care in clinical settings. Although other efforts have been made to set dementia care quality standards, such as those pioneered by RAND in its series Assessing Care of Vulnerable Elders (ACOVE), practitioners, healthcare systems, and insurers have not widely embraced implementation. This executive summary (full manuscript available at www.neurology.org) reports on a new measurement set for dementia management developed by an interdisciplinary Dementia Measures Work Group (DWG) representing the major national organizations and advocacy organizations concerned with the care of individuals with dementia. The American Academy of Neurology (AAN), the American Geriatrics Society, the American Medical Directors Association, the American Psychiatric Association, and the American Medical Association-convened Physician Consortium for Performance Improvement led this effort. The ACOVE measures and the measurement set described here apply to individuals whose dementia has already been identified and properly diagnosed. Although similar in concept to ACOVE, the DWG measurement set differs in several important ways; it includes all stages of dementia in a single measure set, calls for the use of functional staging in planning care, prompts the use of validated instruments in patient and caregiver assessment and intervention, highlights the relevance of using palliative care concepts to guide care before the advanced stages of illness, and provides evidence-based support for its recommendations and guidance on the selection of instruments useful in tracking patient-centered outcomes. It also specifies annual reassessment and updating of interventions and care plans for dementia-related problems that affect families and other caregivers as well as individuals with dementia. Here, a brief synopsis of why major reforms in healthcare design and delivery are needed to achieve substantive improvements in the quality of care is first provided, and then the final measures approved for publication, dissemination, and implementation are listed.


Subject(s)
Dementia/therapy , Disease Management , Neurology/standards , Quality Improvement , Aged , Humans
5.
Am J Occup Ther ; 67(6): 704-10, 2013.
Article in English | MEDLINE | ID: mdl-24195904

ABSTRACT

This article represents the efforts of an interdisciplinary work group, the Dementia Measures Work Group (DWG), composed of representatives of diverse national organizations who convened specifically to define optimal standards of dementia care for individual practitioners as well as multidisciplinary teams. The DWG measurement set includes all stages of dementia in a single measure set, calls for the use of functional staging in planning care, prompts the use of validated instruments in patient and caregiver assessment and intervention, highlights the relevance of using palliative care concepts to guide care prior to the advanced stages of illness, and provides evidence-based support for its recommendations and guidance on the selection of instruments for tracking patient-centered outcomes. In addition, it specifies annual reassessment and updating of interventions and care plans for dementia-related problems that affect families and other caregivers as well as patients.


Subject(s)
Dementia/therapy , Occupational Therapy/standards , Patient Outcome Assessment , Quality Improvement , Ambulatory Care/standards , Caregivers , Counseling/standards , Humans , Patient Care Planning
7.
Psychiatr Clin North Am ; 35(1): 203-29, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22370499

ABSTRACT

We have already entered a new, more exciting, and hopeful era in the treatment of late-life depression. The increasing numbers of older adults who are surviving to more advanced ages and the greater recognition of late-life depression's prevalence and impact on quality of life emphasize how important it is to detect and treat this disorder. Our increasing repertoire of evidence-based psychotherapeutic, pharmacologic, and neurotherapeutic treatment interventions offers many treatment alternatives, allowing substantial individualization of treatment approach. Demonstration of the effectiveness of depression treatment in primary care suggests the feasibility of increasing our patients' access to care. Growing appreciation of the pathophysiology of depression and its interrelationships with cognitive impairment may increase our ability to limit or delay certain aspects of cognitive impairment through more aggressive treatment of depression. Improved recognition and treatment of late-life depression holds great potential for improving physical and mental health in later life, reducing disability in later years, and improving quality of life.


Subject(s)
Antidepressive Agents/classification , Dementia/complications , Depressive Disorder , Geriatric Assessment/methods , Primary Health Care , Age Factors , Aged, 80 and over , Antidepressive Agents/pharmacology , Antidepressive Agents/therapeutic use , Cognition Disorders/complications , Cognition Disorders/psychology , Dementia/psychology , Depressive Disorder/complications , Depressive Disorder/diagnosis , Depressive Disorder/drug therapy , Diagnosis, Differential , Humans , Hypothalamo-Hypophyseal System/physiopathology , Pituitary-Adrenal System/physiopathology , Psychiatric Status Rating Scales
10.
Am J Geriatr Psychiatry ; 15(7): 604-10, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17586784

ABSTRACT

OBJECTIVE: To assess the relationships among depressive signs and symptoms and left versus right temporal-parietal cerebral blood volumes (CBVs) in elderly patients with a primary complaint of memory loss. METHODS: Total Geriatric Depression Scale Short Form (GDS-SF) scores, left and right temporal-parietal cerebral blood volume values, and other prospectively recorded data were obtained via chart review of 24 patients aged >/=65 years, evaluated between 1995 and 2000 at McLean Hospital for a primary complaint of memory loss. Multivariate regression analyses were carried out with GDS-SF total scores as outcome variables, with CBV values as explanatory factors and with several patient characteristics as covariates. RESULTS: Depressive symptoms, as measured by the GDS-SF, were significantly associated with decreased left/right temporal-parietal CBV ratios (beta regression coefficient = -20.7; t [df = 22] = -2.96, p = 0.007). These findings remained statistically significant after controlling for age, sex, Mini-Mental State Exam (MMSE) score, years of education, years of memory loss, and handedness (beta regression coefficient = -16.7; t [df = 16] = -2.67, p = 0.017). CONCLUSION: In this study, severity of depressive symptoms as measured by the GDS-SF in patients >/=65 years old who presented with a primary complaint of memory loss was associated with decreased left/right temporal-parietal CBV ratios, independently of age, sex, MMSE score, years of education, years of memory loss, and handedness. These findings suggest that in the presence of cognitive decline, increased depressive signs and symptoms may be associated with decreased left/right temporal-parietal CBV ratios.


Subject(s)
Depressive Disorder, Major , Functional Laterality/physiology , Magnetic Resonance Imaging , Memory Disorders , Parietal Lobe/blood supply , Parietal Lobe/physiopathology , Temporal Lobe/blood supply , Temporal Lobe/physiopathology , Aged , Aged, 80 and over , Cerebrovascular Circulation/physiology , Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/epidemiology , Depressive Disorder, Major/physiopathology , Female , Humans , Male , Memory Disorders/diagnosis , Memory Disorders/epidemiology , Memory Disorders/physiopathology , Neuropsychological Tests , Prospective Studies , Retrospective Studies , Severity of Illness Index , Surveys and Questionnaires
12.
Front Neuroendocrinol ; 27(2): 170-9, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16376420

ABSTRACT

Initial investigations into the mechanistic basis of aggression focused on the role of testosterone (T) and a variety of studies on non-human animals found that elevated T levels promote aggression. However, many correlational studies have not detected a significant association between aggression and peripheral T levels. One reason for this inconsistency may be due to differential metabolism of T within the brain, in particular, the conversion of T to estrogen by aromatase. Thus, differences in aromatase enzyme activity, estrogen receptor expression, and related cofactors may have important effects on how steroids affect aggressive behavior. Hormone manipulation studies conducted in a wide variety of species indicate that estrogens modulate aggression. There is also growing evidence that social experience has important effects on the production of estrogen within the brain, and some cases can not be explained by androgenic regulation of aromatase. Such changes in central aromatase activity may play an important role in determining how social experiences affect the probability of whether an individual engages in aggressive behavior. Although studies have been conducted in many taxa, there has been relatively little integration between literatures examining aggression in different species. In this review, we compare and contrast studies examining aggression in birds, mammals, and humans. By taking an integrative approach to our review, we consider mechanisms that could explain species differences in how estrogen modulates aggression.


Subject(s)
Aggression/physiology , Aromatase/metabolism , Brain/enzymology , Environment , Estrogens/metabolism , Testosterone/metabolism , Animals , Birds , Humans , Learning/physiology , Mammals , Receptors, Estrogen/metabolism , Sex Factors , Species Specificity
13.
Am J Psychiatry ; 159(7): 1225-7, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12091203

ABSTRACT

OBJECTIVE: This study investigated the efficacy and safety of short-term estrogen therapy in decreasing noncognitive signs and symptoms of dementia in demented elderly patients. METHOD: Sixteen moderately to severely demented elderly patients with aggressive behavioral disturbances were randomly assigned to receive conjugated equine estrogens or placebo in a 4-week clinical trial. Frequency and severity of noncognitive signs and symptoms of dementia, as assessed with the Dementia Signs and Symptoms Scale, were compared between estrogen and placebo groups. Data were analyzed with intent-to-treat and regression modeling methods. RESULTS: Estrogen therapy was associated with a significantly greater improvement on the Dementia Signs and Symptoms Scale total score than placebo. All five Dementia Signs and Symptoms Scale subscale comparisons favored estrogen therapy. No adverse effects were observed. CONCLUSIONS: These preliminary data suggest that short-term estrogen therapy may safely decrease the frequency and severity of noncognitive signs and symptoms of dementia in elderly patients.


Subject(s)
Dementia/diagnosis , Dementia/drug therapy , Estrogens, Conjugated (USP)/therapeutic use , Age Factors , Aged , Aged, 80 and over , Aggression/psychology , Comorbidity , Dementia/epidemiology , Dementia/psychology , Double-Blind Method , Drug Administration Schedule , Estrogens, Conjugated (USP)/administration & dosage , Female , Humans , Male , Placebos , Psychiatric Status Rating Scales , Severity of Illness Index , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...